Trial reportImmunity, inflammation and disease2026
Efficacy, Safety and Immunomodulatory Effect of Intramuscular Injections of Autologous Whole Blood Into Acupoints in Patients With Atopic Dermatitis: A Randomized Controlled Trial.
Trial report in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy, Safety and Immunomodulatory Effect of Intramuscular Injections of Autologous Whole Blood Into Acupoints in Patients With Atopic Dermatitis: A Randomized Controlled Trial.Immunity, inflammation and disease · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionThe use of acupoint autohemotherapy (A-AHT) has shown promise in the management of atopic dermatitis (AD); however, the lack of rigorously controlled comparative studies presents a significant obstacle to the establishment of strong clinical evidence.
aimWe aimed to compare the safety and efficacy of A-AHT and subcutaneous Dupilumab injection in AD patients. PATIENTS AND
methodsThirty-one patients with moderate-to-severe AD were randomly allocated to receive 8 times of weekly intramuscular autologous whole blood (AWB) injection into bilateral Zusanli (ST36), Xuehai (SP10), Quchi (LI11) and Ashi points (n = 23) or subcutaneous Dupilumab injection with the dosage based on age/weigh (n = 8) for 8 weeks. Changes in SCORAD value, Visual Analog Scale (VAS) scores for pruritus and sleep quality, serum total IgE, cytokines including interleukin (IL)-2, IL-4, IL-6, IL-10, interferon (IFN)-γ, and tumor necrosis factor (TNF)-α levels were assessed at baseline and week 8.
resultsBoth treatments resulted in a reduction of SCORAD values and serum IgE levels compared to their baseline (p < 0.001 or p < 0.05); however, no significant differences were observed between the two groups. When compared to the Dupilumab group, A-AHT exhibited greater effectiveness in improving the VAS scores for pruritus and sleep quality. Within the A-AHT group, there was a significant improvement in the serum levels of IL-2, IL-6, IL-10, TNF-α, and IFN-γ at week 8 compared to baseline (p < 0.05 or p < 0.01), whereas no changes were noted in the Dupilumab group. Serious adverse events were not observed.
conclusionsA-AHT appears to be effective in treating moderate-to-severe AD, warranting further studies to validate these results. TRAIL REGISTRATION: ChiCTR2300068163.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.